MIC2211

MIC2211 is a small molecule drug candidate being developed by Micar Innovation (also known as Micar21) for the treatment of hyperekplexia, a rare neurological disorder. Hyperekplexia, often referred to as startle disease, is characterized by an exaggerated startle response to sudden tactile or auditory stimuli and neonatal muscle stiffness. The compound was identified using Micar Innovation's proprietary AI-driven, structure-based in silico drug discovery platform, which aims to identify novel leads for unmet medical needs. As of early 2024, MIC2211 is in the preclinical stage of development, specifically within the therapeutic identification phase. While hyperekplexia is traditionally associated with mutations in glycine receptors or transporters, the specific biological target of MIC2211 has not been publicly disclosed by the developer.